Onkure Therapeutics, INC 8-K filings

OnKure Therapeutics reported Q2 2026 financial results, highlighting $176 million in cash and continued progress on its next-generation PI3K inhibitor programs, OKI-345 and OKI-355, with IND submissions planned for H1 2027.

OnKure Therapeutics reported first quarter 2026 financial results, highlighting the nomination of two new drug candidates, OKI-355 and OKI-345, and a $150 million private placement to fund clinical development.

OnKure Therapeutics secured ~$150 million via a private placement of common stock and pre-funded warrants, granted board nomination rights to the lead investor, and outlined pipeline milestones, including INDs for next‑gen PI3K pan‑mutant programs in H1 2027.

OnKure Therapeutics, Inc. has entered into a sales agreement with Leerink Partners LLC to establish an 'at-the-market' equity offering program for its Class A common stock.

OnKure Therapeutics reported its third quarter 2025 financial results, revealing increased net losses and a delay in the release of initial clinical data for its lead oncology program, OKI-219, until Q1 2026.

OnKure Therapeutics reported second quarter 2025 financial results and provided a business update, highlighting progress in its PIKture-01 clinical trial and a cash runway into Q4 2026.

OnKure Therapeutics, Inc. has released an updated corporate presentation showcasing positive early Phase 1 clinical trial results for its highly selective PI3K inhibitor, OKI-219, and confirming a cash runway extending into the fourth quarter of 2026.

OnKure Therapeutics, Inc. announced the successful election of two Class I directors and the ratification of KPMG LLP as its independent registered public accounting firm at its 2025 Annual Meeting of Stockholders.

OnKure Therapeutics announced its Q1 2025 financial results, highlighting progress in its PIKture-01 trial and plans for a new pan-mutant selective development candidate.

OnKure Therapeutics announced its Q4 and full year 2024 financial results, highlighting progress in its PI3Ka inhibitor programs and a cash runway sufficient to fund operations into Q4 2026.

OnKure Therapeutics reports encouraging preliminary safety, tolerability, and pharmacokinetic data from its first-in-human trial of OKI-219, a mutant-selective PI3K inhibitor.

OnKure Therapeutics, formerly Reneo Pharmaceuticals, completed its merger with Legacy OnKure, appointed KPMG as its new auditor, and released unaudited financials for the period ending September 30, 2024.

OnKure Therapeutics, Inc. has finalized its merger with Reneo Pharmaceuticals, Inc., and secured $65 million in a private placement, positioning the company to advance its pipeline of precision oncology therapies.

Reneo Pharmaceuticals' stockholders have approved the merger with OnKure and related proposals, including the issuance of shares and a reverse stock split, at a special meeting held on September 26, 2024.

Reneo Pharmaceuticals has supplemented its merger proxy statement to address lawsuits alleging misrepresentations and omissions related to its proposed merger with OnKure, Inc.

Reneo Pharmaceuticals has terminated its Chief Development Officer, Ashley F. Hall, effective September 13, 2024, as part of its merger with OnKure, Inc. and the cessation of its historical drug development efforts.

Reneo Pharmaceuticals reported a reduced net loss for Q2 2024 and provided an update on its planned merger with OnKure, Inc.

Reneo Pharmaceuticals and OnKure, Inc. have agreed to merge, forming a Nasdaq-listed company focused on advancing OnKure's precision oncology pipeline, supported by a $65 million PIPE financing.

Reneo Pharmaceuticals announced its Q1 2024 financial results, highlighting a reduced net loss and ongoing strategic review following the discontinuation of its lead drug development program.

Reneo Pharmaceuticals reported its Q4 and full year 2023 financial results, highlighted by a significant net loss and a strategic shift following the failure of its pivotal STRIDE study.

Reneo Pharmaceuticals plans a second workforce reduction of approximately 20% by February 29, 2024, incurring an estimated $1.7 million in charges.